Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 8933 results

  1. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Pain management (young people and adults)

    Awaiting development Reference number: GID-QS10093 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Sleep disordered breathing

    Awaiting development Reference number: GID-QS10096 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Heart valve disease in adults

    Awaiting development Reference number: GID-QS10101 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Infant, children and young people's experience of health care

    Awaiting development Reference number: GID-QS10102 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    Awaiting development Reference number: GID-TA11866 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  11. NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]

    In development Reference number: GID-TA10205 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  13. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ianalumab for treating active Sjogren's syndrome [ID6634]

    Awaiting development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development